within Pharmacolibrary.Drugs.ATC.G;

model G03GA09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333336e-07,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0099,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0024,
    k12             = 0.047,
    k21             = 0.047
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03GA09</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Corifollitropin alfa is a recombinant gonadotropin used as a long-acting follicle-stimulating hormone (FSH) analog in controlled ovarian stimulation for assisted reproductive technology (ART) procedures. It is approved for the treatment of infertility in women undergoing ovarian stimulation for in vitro fertilization.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy premenopausal women (18-39 years) following a single subcutaneous injection.</p><h4>References</h4><ol><li><p>Loutradis, D, et al., &amp; Antsaklis, A (2009). Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility. <i>Current opinion in investigational drugs (London, England : 2000)</i> 10(4) 372–380. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19337959/\">https://pubmed.ncbi.nlm.nih.gov/19337959</a></p></li><li><p>de Kam, PJ, et al., &amp; Thomsen, T (2015). Single therapeutic and supratherapeutic doses of corifollitropin alfa, a sustained follicle stimulant, do not prolong the QTcF-interval in healthy postmenopausal volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 53(9) 772–782. DOI:<a href=\"https://doi.org/10.5414/CP202363\">10.5414/CP202363</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26227099/\">https://pubmed.ncbi.nlm.nih.gov/26227099</a></p></li><li><p>Fauser, BC, et al., &amp; Baird, DT (2009). Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. <i>Human reproduction update</i> 15(3) 309–321. DOI:<a href=\"https://doi.org/10.1093/humupd/dmn065\">10.1093/humupd/dmn065</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19182099/\">https://pubmed.ncbi.nlm.nih.gov/19182099</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03GA09;
